FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo

Welcome to the Oncology Brothers Podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Saby George from Roswell Park Comprehensive Cancer Center to discuss the recent approval of subcutaneous nivolumab based on the CheckMate-67T study.
Join us as we delve into:
•⁠  ⁠The study design and findings of CheckMate-67T
•⁠  ⁠The implications of subcutaneous nivolumab for patients and healthcare providers
•⁠  ⁠Safety signals and side effects associated with the new formulation
•⁠  ⁠The significant time savings for patients receiving treatment
•⁠  ⁠Real-world experiences from patients involved in the trial

This episode highlights how the subcutaneous formulation of nivolumab can enhance patient care by reducing time spent in infusion centers while maintaining efficacy and safety.

Tune in to learn more about this exciting advancement in cancer treatment and its potential impact on patient quality of life! Don't forget to like, subscribe, and check out our other episodes for more insights on FDA drug approvals, conference highlights, and treatment algorithms. We are the Oncology Brothers!

YouTube: https://youtu.be/4blP8jqizUQ

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

Subscribe to our channel for more insights on oncology treatments and patient care!